Scaling-up recombinant plasmid DNA for clinical trial: Current concern, solution and status

被引：25

作者：

Ismail, Ruzila ^{[2
]}

Allaudin, Zeenathul Nazariah ^{[1
]}

Lila, Mohd-Azmi Mohd ^{[1
]}

机构：

[1] Univ Putra Malaysia, Fac Vet Med, Dept Pathol & Microbiol, Serdang 43400, Selangor, Malaysia

[2] Univ Putra Malaysia, Inst Biosci, Lab Immunotherapeut & Vaccines, Serdang 43400, Selangor, Malaysia

来源：

VACCINE | 2012年 / 30卷 / 41期

关键词：

DNA vaccine; Host genome; Plasmid DNA; Resistance marker; Synthetic vector; TRANSGENE EXPRESSION; GENE-THERAPY; REPLICATION ORIGIN; SYNTHETIC PROMOTER; CPG MOTIFS; SELECTION; SEQUENCE; VECTORS; MAINTENANCE; VACCINE;

D O I：

10.1016/j.vaccine.2012.02.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Gene therapy and vaccines are rapidly developing field in which recombinant nucleic acids are introduced in mammalian cells for enhancement, restoration, initiation or silencing biochemical function. Beside simplicity in manipulation and rapid manufacture process, plasmid DNA-based vaccines have inherent features that make them promising vaccine candidates in a variety of diseases. This present review focuses on the safety concern of the genetic elements of plasmid such as propagation and expression units as well as their host genome for the production of recombinant plasmid DNA. The highlighted issues will be beneficial in characterizing and manufacturing plasmid DNA for save clinical use. Manipulation of regulatory units of plasmid will have impact towards addressing the safety concerns raised in human vaccine applications. The gene revolution with plasmid DNA by alteration of their plasmid and production host genetics will be promising for safe delivery and obtaining efficient outcomes. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：5914 / 5920

页数：7

共 83 条

[81] Controlling the kinetics of transgene expression by plasmid design [J].